X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2022/09/30/2525815/0/en/InvestmentPitch-Media-Video-Discusses-Resverlogix-and-its-Focus-on-Apabetalone-s-Future-Development-for-the-Prevention-and-Treatment-of-Post-COVID-19-Conditions.html
https://www.globenewswire.com/news-release/2022/09/28/2524164/0/en/Resverlogix-Confirms-Focus-on-Treatment-of-Post-COVID-19-Conditions.html
https://www.globenewswire.com/news-release/2022/08/22/2502072/0/en/Resverlogix-Publishes-New-Data-Highlighting-Apabetalone-s-Benefit-in-Non-alcoholic-Fatty-Liver-Disease.html
https://www.globenewswire.com/news-release/2022/06/22/2466722/0/en/Resverlogix-Announces-Voting-Results-from-the-2022-Meeting-of-Shareholders.html
https://www.globenewswire.com/news-release/2022/06/08/2458596/0/en/Resverlogix-Announces-New-Research-Findings-Highlighting-the-Safety-of-BD2-selective-BET-Inhibitors.html
https://www.globenewswire.com/news-release/2022/05/09/2438456/0/en/Resverlogix-Announces-Type-C-Meeting-with-FDA-for-CORAL-a-Phase-3-High-risk-COVID-19-Outpatient-Study.html
https://www.globenewswire.com/news-release/2022/04/19/2425031/0/en/Resverlogix-Announces-One-Year-Extension-of-Debenture.html
https://www.clinicaltrialsarena.com/news/resverlogix-apabetalones-trial-covid-19/
https://www.globenewswire.com/news-release/2022/01/18/2368307/0/en/Resverlogix-Announces-Commencement-of-Patient-Enrollment-and-Dosing-in-a-Phase-2b-Trial-for-a-Promising-Canadian-Developed-COVID-19-Treatment.html
Market Place
Share 
